Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,838
datasets available to search
ShareScore release 0.9.0
Dataset results
1,838 results for “Endometrial”
Data from: Macrophage migration inhibitory factor is involved in ectopic endometrial tissue growth and peritoneal-endometrial tissue interaction in vivo: a plausible link to endometriosis development
Pelvic inflammation is a hallmark of endometriosis pathogenesis and a major cause of the disease's symptoms. Abnormal immune and inflammatory changes may not only contribute to endometriosis-major symptoms, but also contribute to ectopic endometrial tissue growth and endometriosis development. A major pro-inflammatory factors found elevated in peritoneal fluid of women with endometriosis and to be overexpressed in peritoneal fluid macrophages and active, highly vascularized and early stage endometriotic lesions, macrophage migration inhibitory factor (MIF) appeared to induce angiogenic and inflammatory and estrogen producing phenotypes in endometriotic cells in vitro and to be a possible therapeutic target in vivo. Using a mouse model where MIF-knock out (KO) mice received intra-peritoneal injection of endometrial tissue from MIF-KO or syngeneic wild type (WT) mice and vice versa, our current study revealed that MIF genetic depletion resulted in a marked reduction ectopic endometrial tissue growth, a disrupted tissue structure and a significant down regulation of the expression of major inflammatory (cyclooxygenease-2), cell adhesion (αv and β3 integrins), survival (B-cell lymphoma-2) and angiogenic (vascular endothelial cell growth) factorsrelevant to endometriosis pathogenesis, whereas MIF add-back to MIF-KO mice significantly restored endometriosis-like lesions number and size. Interestingly, cross-experiments revealed that MIF presence in both endometrial and peritoneal host tissues is required for ectopic endometrial tissue growth and pointed to its involvement in endometrial-peritoneal interactions. This study provides compelling evidence for the role of MIF in endometriosis development and its possible interest for a targeted treatment of endometriosis.
MITO END-3: efficacy of Avelumab immunotherapy according to molecular profiling in first line endometrial cancer therapy
<p>Immunotherapy combined to chemotherapy significantly improves progression free survival compared to first line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cases. New biomarkers might help to select patients that may have benefit among those with a microsatellite-stable (MSS) tumor.</p> <p>Methods.</p> <p>In a pre-planned translational analysis of the MITO END-3 trial we assessed the significance of genomic abnormalities in patients randomized to standard carboplatin/paclitaxel without or with avelumab.</p> <p>Results.</p> <p>Out of 125 randomized patients, 109 had samples eligible for Next Generation Sequencing (NGS) analysis and 102 had MSI tested. According to The Cancer Genome Atlas (TCGA) there were 29 cases MSI-H, 26 MSS TP53 wild type (wt), 47 MSS TP53 mutated (mut), and one case with <em>POLE</em> mutation. Four mutated genes were present in more than 30 % of cases: <em>TP53</em>,<em> PIK3CA</em>,<em> ARID1A</em>,<em> PTEN</em>. Eleven patients (10 %) had a BRCA 1/2 mutation (5 in MSI-H and 6 in MSS). High TMB (≥ 10Muts/Mb) was observed in all MSI-H patients, in 4 out of 47 MSS/<em>TP53</em>mut, and in no case in the MSS/<em>TP53</em>wt category. The effect of avelumab on progression-free survival (PFS) significantly varied according to TCGA categories, being favorable in MSI-H and worst in MSS/TP53mut (P interaction=0.003); a similar non-significant trend was seen in survival analysis. <em>ARID1A</em> and <em>PTEN</em> also showed a statistically significant interaction with treatment effect, that was better in presence of the mutation (<em>ARID1A</em> P interaction=0.01; <em>PTEN</em> P interaction=0.002).</p> <p>Conclusion</p> <p>The MITO END-3 trial results suggest that <em>TP53 </em>mutation is associated with poor effect of avelumab, while mutations of <em>PTEN</em> and <em>ARID1A</em> are related to a positive effect of the drug in patients with advanced endometrial cancer.</p>
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
ClinicalTrials.gov study NCT01536392. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Uterine Manipulator on Recurrence and Mortality of Endometrial Cancer
ClinicalTrials.gov study NCT02943811. IPD Sharing: NO. Countries: 0. Publications: 2.
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
ClinicalTrials.gov study NCT01289041. IPD Sharing: Not stated. Countries: 13. Publications: 0.
An Endometrial Cancer Chemoprevention Study of Metformin
ClinicalTrials.gov study NCT01697566. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
ClinicalTrials.gov study NCT01111461. IPD Sharing: Not stated. Countries: 8. Publications: 0.
FitEx for Endometrial Cancer Survivors: Initial Efficacy
ClinicalTrials.gov study NCT05737745. IPD Sharing: NO. Countries: 1. Publications: 0.
Photoacoustic Endoscopy in Endometrial Cancer
ClinicalTrials.gov study NCT01498237. IPD Sharing: Not stated. Countries: 0. Publications: 31.
Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion
ClinicalTrials.gov study NCT01979003. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
ClinicalTrials.gov study NCT00723255. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
ClinicalTrials.gov study NCT05542407. IPD Sharing: NO. Countries: 1. Publications: 0.
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
ClinicalTrials.gov study NCT03485729. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
ClinicalTrials.gov study NCT05524389. IPD Sharing: Not stated. Countries: 0. Publications: 1.
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
ClinicalTrials.gov study NCT00910091. IPD Sharing: Not stated. Countries: 12. Publications: 0.
Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation
ClinicalTrials.gov study NCT06672341. IPD Sharing: Not stated. Countries: 0. Publications: 17.
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
ClinicalTrials.gov study NCT06518564. IPD Sharing: YES. Countries: 1. Publications: 0.
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
ClinicalTrials.gov study NCT01642082. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
ClinicalTrials.gov study NCT05036681. IPD Sharing: NO. Countries: 1. Publications: 0.
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
ClinicalTrials.gov study NCT05796518. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.